| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 30th December 2020 | Thomas Woiwode | 1,347,709 | Open or private purchase | $3.71 | $5,000,000.39 |
| 14th December 2020 | Thomas Woiwode | 12,783 | Other acquisition or disposition | $0.00 | |
| 20th October 2020 | Thomas Woiwode | 198,485 | Conversion of derivative | $0.00 | |
| 20th October 2020 | Thomas Woiwode | 200,000 | Open or private purchase | $15.00 | $3,000,000.00 |
| 20th October 2020 | Thomas Woiwode | 463,959 | Conversion of derivative | $0.00 | |
| 20th October 2020 | Thomas Woiwode | 198,839 | Conversion of derivative | $0.00 | |
| 20th October 2020 | Thomas Woiwode | 2,145,991 | Conversion of derivative | $0.00 | |
| 20th October 2020 | Thomas Woiwode | 85,065 | Conversion of derivative | $0.00 | |
| 17th August 2020 | Erin Jones | 10,000 | Exercise of derivative | $0.35 | $3,450.00 |
| 3rd March 2020 | Thomas Woiwode | 1,049,175 | Conversion of derivative | $0.00 |
Gritstone Oncology
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Gritstone Oncology, Inc. is a clinical-stage biotechnology company. The company is developing the next generation of cancer immunotherapies to fight multiple cancer types.
Ticker: GRTS
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1656634
Employees: 174
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $63 M (0%)
Marketable Securities, Current: $29 M (-58%)
Other Assets, Current: $290 Th (0%)
Assets, Current: $94 M (-28%)
Property, Plant and Equipment, Net: $25 M (0%)
Assets: $146 M (-21%)
Accounts Payable, Current: $4 M (-6%)
Accrued Liabilities, Current: $138 Th (-86%)
Liabilities, Current: $19 M (-1%)
Liabilities: $49 M (-1%)
Common Stock, Value, Issued: $17 Th (0%)
Common Stock, Shares, Issued: $38 M (0%)
Retained Earnings (Accumulated Deficit): $273 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $50 Th (108%)
Stockholders' Equity (Parent): $96 M (0%)
Liabilities and Equity: $146 M (-21%)
Revenue: $488 Th (-72%)
Research and Development: $21 M (-51%)
General and Administrative Expenses: $5 M (-50%)
Operating Income/Loss: $26 M (-50%)
News
Gritstone Oncology Announces $110 Million Private Placement
23rd December 2020
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020